Immune response to second vaccination series of hepatitis B virus among booster dose non-responders

Salama, Iman I.; Sami, Samia M.; Salama, Somaia I; Rabah, Thanaa M.; Etreby, Lobna A. El; Hamid, Amany T. Abdel; Elmosalami, Dalia M.; El-Hariri, Hazem; Said, Zeinab N.

doi:10.1016/j.vaccine.2016.02.050

Cited by 11 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With two additional doses, the PSR of Group I significantly increased from 95.65% to 99.67%, which demonstrates that most people who have lost immunological memory can receive protective antibodies through three doses of booster vaccination. The studies reported by Lu et al 19 and Salama et al 27 obtained the same result. After stratifying by age, the anti-HBs GMT of the subjects aged 5-9 y was much higher than that of those aged 10-15 y at 1 month after dose 1 in both Group I and Group II, which indicates that subjects aged 5-9 y had a better immune response.…”

Section: Discussionsupporting

confidence: 72%

The effects of booster vaccination of hepatitis B vaccine on children 5–15 years after primary immunization: A 5-year follow-up study

Yao

Bao

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The aim of this study was to evaluate changes in hepatitis B surface antibody titers (anti-HBs) after booster vaccinations in children aged 5-15 y and to provide suitable immunization strategies. A total of 2208 children were initially enrolled in screening, and 559 children were finally included. The participants were divided into 2 groups according to their pre-booster anti-HBs levels: Group I, <10 mIU/ml and Group II, ≥10 mIU/ml. Group I was administered 3 doses of booster hepatitis B vaccine (0-1-6 months, 10 μg), and Group II was administered 1 dose of booster hepatitis B vaccine (10 μg). The antibody titer changes were examined at 4 time points: 1 month after dose 1 and dose 3, and 1 year and 5 years after dose 3. The protective seroconversion rates at those points were 95.65%, 99.67%, 97.59% and 91.05% (p < 0.001), respectively, in Group I, and 100.00%, 99.87%, 99.66% and 98.21% (χ = 6.04, p = 0.11), respectively, in Group II. The GMT in subjects aged 5-9 y were higher than that in subjects aged 10-15 y in both Group I and Group II at 1 month after dose 1, but no difference was observed at the other three time points. This study demonstrates that booster vaccination has a good medium-term effect. A booster dose for subjects with protective antibodies is not necessary but effective, and 3 doses of hepatitis B vaccination are recommended for those who have lost immunological memory. Receiving booster immunization at the age of 10-15 years may be more appropriate for individuals living in HBV high epidemic areas.

show abstract

Section: Discussionsupporting

confidence: 72%

The effects of booster vaccination of hepatitis B vaccine on children 5–15 years after primary immunization: A 5-year follow-up study

Yao

Bao

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…A total of 967 children (90.4%) achieved a positive response. Of the 103 children with a nonprotective antibody titre, 94 were given another 2 doses of vaccine: 87 subjects (92.3%) achieved a positive titre, while 7 (7.7%) remained negative . The results and the composition of the sample are similar to those of our study; the main difference is that we have evaluated the difference in seroprevalence among subjects who received the vaccine at different ages (1 and 12 years).…”

Section: Discussionsupporting

confidence: 77%

HBV seroprevalence after 25 years of universal mass vaccination and management of non‐responders to the anti‐Hepatitis B vaccine: An Italian study among medical students

Bianchi

Gallone

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

According to international guidelines, healthcare workers and medical students immunized against HBV are periodically tested for anti-HBs IgG. Subjects who show an anti-HBs titre <10 mUI/mL must receive additional vaccine doses to induce a measurable antibody response. This study aimed to evaluate the long-time immunogenicity of anti-hepatitis B vaccination in a sample of medical students and residents of the University of Bari who attended the Hygiene Department for biological risk assessment (April 2014-June 2017). The strategy for the management of nonresponder subjects was evaluated. A total of 3676 students and residents were invited for testing according to a standardized protocol. Anti-HBs IgG was tested for in 3140 (85.4%) subjects: 1174/3140 (37.7%) subjects were negative. 14.6% (128/808) of subjects who received the vaccine during their 12th year of life and 45.8% (1056/2305) of subjects immunized during the first year of life (P < 0.0001) were negative. 1005/1174 (85.6%) seronegative subjects received a booster dose, and 903/1005 (89.9%) were tested for anti-HBs 1 month after the booster dose: 82/903 (9.1%) subjects were still negative. Of these, 56/82 (68.3%) received 2 additional doses of vaccine and 52/56 (92.9%) were tested 1 month after the third dose: 50/52 subjects (96.2%) developed a positive titre. In conclusion, several medical students, immunized at birth or at young age against HBV, did not develop protective titres against the virus. Our management strategy (booster retest; for negative subjects, 2 doses and retest) seems consistent with the purpose of evidencing immunological memory.

show abstract

“…Only eight refugee children (2.7%) had a positive Mantoux ≥10 mm reaction, all were previously vaccinated with BCG and all had a normal CXR. Two of them originated from Congo while the remaining six from Afghanistan, both countries with a high prevalence of tuberculosis where respective immunization has been provided under the GAVI program [29]. As known, BCG vaccination may cause a false-positive result following Mantoux testing that can be clarified through interferon-gamma release assays (IGRAs).…”

Section: Discussionmentioning

confidence: 99%

Clinical and laboratory evaluation of new immigrant and refugee children arriving in Greece

et al. 2017

View full text Add to dashboard Cite

BackgroundMigrant children are a population at risk for various health problems. Despite the increased inflow of migrants in Greece, data regarding their health assessment are lacking. This study aims to describe the clinical and certain laboratory characteristics and identify possible associations in a group of new immigrant (I) and refugee (R) children, arriving in Athens, Greece.MethodsA prospective, cross- sectional study was performed in a migrant outpatient clinic of a tertiary Children’s hospital. All immigrant and refugee children, examined to obtain a health certificate, within 3 months of their arrival in the country, were enrolled. Clinical and laboratory information was collected in a pre- designed form. We applied multiple logistic regression models to investigate the association between the child’s status (immigrant vs refugee) and health indicators controlling for possible confounding effects, mainly of age and area of origin.ResultsFrom 2010 to 2013, a total of 300 children (I/R:138/162) with a mean age of 7.08 (range 1–14) years were included. Overall, 79.3% presented unknown vaccination status, 21.3% dental and 7.3% additional clinical problems. Latent tuberculosis was identified in 2.7%, while anemia, low serum ferritin and eosinophilia were found in 13.7%, 17.3%, and 22.7% of subjects, respectively. 57.7% had protective antibodies to hepatitis B surface antigen (anti-HBs ≥ 10 IU/L) and 30.6% elevated blood lead levels (EBLLs). Immigrants had less likely unknown immunization (OR = 0.25, p < 0.001), but had increased odds of low ferritin (OR = 1.97, p = 0.043), EBLLs (OR = 2.97, p = 0.001) and protective anti-HBs (OR = 1.79, p = 0.03). Age was inversely associated with anemia (OR = 0.0.89, p = 0.017), low ferritin (OR = 0.91, p = 0.027), EBLLs (OR = 0.86, p = 0.001) or positive anti-HBs (OR = 0.92, p = 0.025). Children from Europe or Africa presented decreased probability of EBLLs (OR = 0.31, p = 0.001, and OR = 0.15, p = 0.005, respectively) compared to those from Asia.ConclusionsNew immigrant and refugee children presented distinct clinical problems and certain laboratory abnormalities. Some of these health issues differed according to their migration status, age and geographic area of origin. These findings provide evidence that may assist the optimal approach of this vulnerable population.

show abstract

Immune response to second vaccination series of hepatitis B virus among booster dose non-responders

Cited by 11 publications

References 17 publications

The effects of booster vaccination of hepatitis B vaccine on children 5–15 years after primary immunization: A 5-year follow-up study

The effects of booster vaccination of hepatitis B vaccine on children 5–15 years after primary immunization: A 5-year follow-up study

HBV seroprevalence after 25 years of universal mass vaccination and management of non‐responders to the anti‐Hepatitis B vaccine: An Italian study among medical students

Clinical and laboratory evaluation of new immigrant and refugee children arriving in Greece

Contact Info

Product

Resources

About